SIMVASTATIN TABLETS

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

SIMVASTATIN

থেকে পাওয়া:

RANBAXY PHARMACEUTICALS CANADA INC.

এটিসি কোড:

C10AA01

INN (আন্তর্জাতিক নাম):

SIMVASTATIN

ডোজ:

10MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

SIMVASTATIN 10MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

21/30/1000

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

HMG-COA REDUCTASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0122415004; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2009-08-13

পণ্য বৈশিষ্ট্য

_ _
_ _
_Page 1 of 45_
PRODUCT MONOGRAPH
SIMVASTATIN TABLETS
(SIMVASTATIN)
USP
5 MG, 10 MG, 20 MG, 40 MG AND 80 MG
LIPID METABOLISM REGULATOR
Ranbaxy Pharmaceuticals Canada Inc., Date of Preparation: August 21,
2009
2680 Matheson Blvd. East, Suite 200
Mississauga, ON L4W 0A5
Canada
SUBMISSION CONTROL NO: 131952
_ _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
......................................................................3
INDICATIONS AND CLINICAL
USE.............................................................................3
CONTRAINDICATIONS
.................................................................................................4
WARNINGS AND
PRECAUTIONS.................................................................................5
ADVERSE
REACTIONS..................................................................................................12
DRUG
INTERACTIONS..................................................................................................14
DOSAGE AND
ADMINISTRATION..............................................................................17
OVERDOSAGE
...............................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
...........................................................19
STORAGE AND
STABILITY.........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................19
PART II: SCIENTIFIC
INFORMATION................................................................................21
PHARMACEUTICAL
INFORMATION.........................................................................21
CLINICAL
TRIALS.........................................................................................................22
DETAILED
PHARMACOLOGY................................................